208340 — PharmAbcine Share News
0.000.00%
Last trade - 00:00- KR₩14bn
- -KR₩36bn
- KR₩4bn
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration
Brief: PharmAbcine Announces First Patient Dosed In nAMD Phase I Trial
Brief: PharmAbcine Receives IND Approval From The Korean MFDS For Phase I Clinical Trial Of Its Novel TIE2 Agonistic Antibody In nAMD
Brief: PharmAbcine Collaborates With MSD To Evaluate PMC-309 With KEYTRUDA
Brief: PharmAbcine Reports Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study
Brief: RNAGENE Signs Collaborative Research Agreement With PharmAbcine To Develop Novel MRNA Therapeutics
Brief: PharmAbcine Announces Joint Patent Application With MSD For Cancer Treatment
Brief: Pharmabcine Announces Submission Of PCT For An Anti-Ang2 Antibody For The Treatment Of Ocular Diseases
Brief: PharmAbcine Reports Collaboration with MSD for Phase II study in mTNBC
Brief: PharmAbcine Enters Into Research Collaboration Agreement With LegoChem Biosciences
Brief: PharmAbcine Signs Research Collaboration Deal With Wuxi Shuangliang Biotechnology To Evaluate Combination Therapy To Treat NSCLC
Brief: Pharmabcine Signs Contract Manufacturing Organization Agreement With Binex For Additional Production Of TTAC-0001
Brief: PharmAbcine Execute An Agreement With Thermo Fisher For Development, Manufacturing Of Its Next-Generation Immune Checkpoint Blockade